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IgA-associated Inhibition of Polymorphonuclear Leukocyte Chemotaxis 
in Neutrophilic Dermatoses 
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Department of Dermatology, University of KielI W. -Germany 
The chemotactic activity of normal human polymor-
phonuclear leukocytes (PMNs) confronted with heat in-
activated sera from patients with psoriasis as well as 
various chronic proliferative diseases was determined 
using modified Boyden chambers. By the addition of 
phorbol myristate acetate (PMA) at a concentration of 1 
ng/ml the chemoattractant activities of the sera were 
greatly potentiated. However, the chemotactic migration 
of normal PMNs was strongly inhibited by sera from 
patients with long standing and wide spread psoriasis, 
pyoderma gangrenosum, severe acne conglobata, Sweet 
syndrome, and some patients with chronic arthritis fol-
lowing rheumatoid fever. In acute guttate psoriasis and 
atopic dermatitis increased migratory activities were 
seen. 
The inhibition of chemotaxis correlated with increased 
serum IgA levels as determined by radial immuno dif-
fusion. Column chromatography (Sephacryl S-300) re-
vealed serum fractions of strong inhibitory potency at a 
molecular weight near 200,000 Dalton. These inhibitory 
fractions were seen in patients with long standing neu-
trophil related diseases and could not be detected in 
normal control sera. It appears that inhibition of PMN 
chemotaxis is a secondary phenomenon and may play an 
autoregulatory role in PMN related inflammation. 
One of the outstanding features in psoriasis is the migration 
of polymorphonuclear leukocytes (PMNs) through t h e epider-
mis toward t h e periphery. These ceUs form micro abscesses 
a long the inner lining of the stratum corneum in response to a 
chemotactic stimulus which is believed to be located within the 
upper epidermis. Several studies have demonstrated ch emotac-
tic complement split products (e.g., C3a, C5a) present in pso-
riatic scales [1-3]. Further, serine esterases capable of activating 
the fifth component into a chemoattractant were found in 
psoriatic stratum corneum [4]. 
R ecently it was shown that the chemotactic activity (CA) of 
PMNs in psoriasis is greatly increased as compared to nonpso-
rjatic controls, when in the Boyden chamber the celis were 
confronted with autologous serum [5]. Evidence was presented 
indicating that fresh sera contained increased ch emo;Ittractan t 
activi ties after incubation with migrating PMNs [5]. These 
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results suggest that in serum ch emoattractants are generated 
in the presence of PMNs. 
In the present study the ability of serum from psoriasis to 
affect chemotactic responses of PMNs is furth er examined with 
respect to t h e state of the disease, its duration and the extent 
of skin involvement. 
The results demonstl'ate t h e presence of a circulating inhib-
itor of PMN ch emotaxis in long standing psoriasis as welJ as in 
infla mmatory diseases in which PMN playa major rol e. 
MATERIALS AND METHODS 
Patients 
All patients investigated were hospitalized and agreed to the pro-
posed in vestigations by wri tten consent. All blood samples were taken 
before any therapy was started. Biopsies were taken in most of these 
derma to logic patients confiJ'ming the clinical diagnosis. 
Sera from patients with rheumatic fever (RF) and chronic glomeru-
lonephri tis (CG) were kindly provided by Dr. M. Gross, 1. Department 
of Internal Medicine, University of Kie l. These patients were regularly 
checked for disease activity. All suffered from progressive joint or 
kidney disease for more than 3 yr. 
For controls hea lthy persons (medical personel, students) were se-
lected. They were 21 to 64 yr of age. 
Preparation of PMNs 
PMNs were isolated by a modification of the method desc ribed by 
Henson (6). Venous blood from healthy non psoriatic donors was drawn 
in to 1/6 vol of acid citrate dextrose (0.085 mol Na:l-citrate, 0.065 mol 
I-I:,-citrate, 2% (w/v) Dextran T70, Pharmacia) , placed in disposable 
plastic tubes and centrifuged (20 min; 500 g). The supernatan t, the 
buffy coat, and the upper portion of the erythrocyte sediment were 
removed. 
The remaining erythu'ocytes and PMN containing sediment were 
gently mixed with 1-1.5 vol of 2.5% gelatine (Merck) in 0.9% NaC I. The 
cell suspension was allowed to sediment in a waterbath at 37°C for 30 
min. The PMN-containing supernatant above the ery throcytes was 
carefully removed and centrifuged at 20°C (10 min; 400 g). Contami-
nating erythrocytes were lysed with 0.85% (w/v) NH.,CI in distilled 
water. The PMN-suspension was centr ifuged at 4°C (10 min; 150 g) 
and washed twice with cold medium TC 199. The fina l cell preparation 
conta ined more than 90% neutrophiJs with a viabi li ty of greater than 
95% as assessed by trypan blue exclusion. 
Chemotaxis A ssay 
50 l ui heat t reated (30 min/56°C) serum was dilu ted with 400 l ui 
medium TC 199 and 50 l uI phorbol myristate acetate (12-0-tetradeca-
noyl-phorbol-13-acetate, PM A, Sigma) in buffer pH 6,5. This was 
prepared just before use by dilution of a dimethylsulphoxide stock 
solution of PMA (1.0 mg/ ml) with ac id sodium acetate buffer, pH 6.5, 
to a final concentration of 10 ng/ ml. The PMA stock solution was kept 
frozen between the experiments (7]. 
Diluted PMA-serum was placed in the lower compartment (150 ~ll) 
of a mod ified Boyden chamber of the bli nd well type. The compar t-
ments of the chamber were separated by a membrane fil ter (cellulose 
nitrate filter , pore size 5.0 /Lm, Sartorius). The upper compar tments 
were filled with 100 III of the PMN-suspension (3 x 10H cells / ml). 
Chambers were incubated for 2.5 hI' at 37°C. 
Thereafter the fLlters were removed, fixed with methanol, stained 
with hematoxylin, cleared with xylene and mounted on glass slides. 
All cells present on the lowermost plane of the filter were counted 
(magnification 500 x ). Five randomly selected Ilelds were counted and 
the average number of cells per high power field (HPF) was expl'essed 
as the average of duplicate or trip licate filters. Casein ("Hammarsten," 
Merck, 4 mg/ml TC 199) was used as a standard chemoattractant for 
every PMN preparation. The range of cells per HPF was 20-40. 
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T he chemotactic activity of the specim ens under study was expressed 
as t h e percentage of chemotactic activity of PMN against casein (= 
relative chemotactic activity, RCA) [5] according to the fo rmula: 
mean nu mber of PMNs per high power field 
RCA = f ' I h ' f x 100 mean o · case ll1 cont ro per 19h power 1eld 
Gel Chrom atography 
1.0 Ill] of fi'esh serum (stored below - 70°C) was chromatographed 
by u s ing Sephacryl S-300 superfine (Pharmacia) in Dulbecco's phos-
p h ate buffe red saline (PBS) . T he dimensions of the column were 1.5 
x 90 cm and the fl ow rates were kept at 5.0 ml per hr resul ting in 5.0 
rnl fractions. E lu ted fractions were measuJ'ed for protein by optical 
density at 280 nm. 
In the chemotaxis assay PMA was added to each fractio n at a final 
concentration of 1 ng/ ml. 
In order to obtain an estimate of the molecular weight of the 
chem otaxis inhibitor the column chromatography (Sephacryl 8 -300 
s u perfine) was calibrated using solutions of blue dextran 2,000, thyro-
globulin (669,000), ferri t in (440,000), catalase (232,000), aldo lase 
(158,000) a nd cytochj'ome C (12,400). Void volumes (Vo) were deter-
ITl i ned by means of blue dextran 2,000 a nd the Ve/ Vo was calculated 
by t he method of Andrews [8]. For determination of IgA the column 
fract ions were 5-fold concent rated (Millipore Ultra fil te rs, exclusion 
liITlit: 10,000 Daltons) and examined by the method of Mancini , Car-
bonara, a nd H eremans [9] using Hyland Immunoplates (Hyla nd Trav-
enol GmbH). 
Dose·R esponse of Different PMA Concentrations on Chemotaxis with 
Serum. 
I n to duplicate vials contain ing 50 IIL I heat-inactivated (56 °C/ 30 min) 
serum 400 ILl of TC 199 and 50 IIL I of a freshly prepared P MA-so lution 
(in 0.1 M acid sodium acetate buffer, pH 6.5) were added at a desired 
fina l concentrat ion of 0.1, 0.5, 1,5, 10, and 100 ng/ ml. 
Determin.a.tion of JgA 
Serum IgA was determined by the method of Ma ncini , Carbona ra, 
and Herema ns [9] using Hyla nd lmmul1o-plates (Hyla nd T ravenol 
GITlbH). The concentrations are given in mg/ dl (WHO values). 
RESULTS 
Potentiation of CA by Phorbol-Myristate·Acetate (PMA) 
Addition of P MA at various concentrations to the serum 
resulted in dose-related potent iation of CA (Fig 1). Maximum 
in~reases in CA were present at a concentration of 1 ng PMA/ 
rrU, wi th higher concentration of PMA no further increase of 
CA was seen, instead, fewer P MNs migrated through the fil ters. 
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F IG 1. R elative chemotactic activity (RCA, ord inate) of normal 
human serum (dilu ted 1:10 wit h T C 199) in the presence of various 
con centrations of PMA (abscissa). Peak chemotactic potentiat ion by 
P MA is seen at a concentra tion of 1 ng/ml. This dose is used in a ll 
s ubsequent experiments of PMA chemotaxis. 
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At a concentration of 10 ng/ ml which has been shown to 
stimulate the release of PMN lysosomal enzymes [10] chemo-
tactic migration was greatly red uced (Fig 1) . R eproducibili ty 
proved to be adequate in this system . For these reasons a 
concentration of 1 ng/ml P MA was used in all subsequent 
experiments. By the addi tion of PMA to the upper and lower 
chamber the possibili ty that this potentiation of chemotaxIS 
was in fact caused by increased chemokinesis could be excluded. 
Chemotactic Activity of Sera from Patients with psoriasis 
A total of 58 sera from patients with different forms of 
psoriasis was analyzed (Fig 2). In all cases the presence of PMA 
augmented the chemoattractant potency of the sera against 
normal P MNs. No difference was fo und in the average RCA 
between psoriatic and nonpsoriatic sera. This confirms previous 
observations obtained with fresh as weU as heatinactivated sera 
without the use of PMA [5]. In psoriasis wide variations were 
seen 'as compared to the control group (Fig 2) . E ighteen sera 
demonstrated very low CA (below 100% RCA) whereas 19 sera 
showed highly increased chemotactic activity with RCA val ues 
above 300%. In the remaining 21 sera no alterations of PMA 
induced CA were detected (Fig 2). 
FUlt her examination of 10 randomly selected sera of each of 
the 2 groups with chemotactic abnormali ties is presented On 
Tables r, II. Whereas the age of the patients and the history of 
psoriasis did not var y significantly in the 2 groups, patients with 
low RCA nearly constantly suffered from the persistent station-
ary type of psoriasis covering wide aJ'eas of the body (more than 
30-50%, T able I). On the other hand high serum chemotactic 
activity correlated with the presence of relapsing psoriasis 
predominantly of the guttate type (Table II) . Also the skin was 
affected to a lesser extent as compared to the former group. 
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F IG 2. R elative chemotactic activity (RCA, ordin.a.te) of heat- inac-
t ivated serum fr om patients with various fo rms of psoriasis. Note wide 
variations of RCA data especia lly in t he psoriatic group. Single dots 
represent average values of duplicate chem otaxis assays. No diffe rence 
is found between psoriatic and nonpsoriatic sera. PMA (I ng/ ml ) was 
used for potent iation of chemotaxis. 
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TABLE I. Clinical data in psoriatic patients with low serum chemolCtctic activity 
IgA (mg/ dl) Patient No. Age/sex" Psoriasis R elapse T ype of Extent of skin RCA " psori asis" since (yr) since (yr) in volvement (%) 
1 56 M 20 6 CS 50 13 
2 12M 10 10 CS 50 10 
3 46M 14 0.3 Guttate 30 32 
425 
360 
253 
434 
230 
454 
321 
575 
302 
224 
4 51 F 
5 58 M 
6 40M 
7 39 M 
8 50 M 
9 29 M 
10 67 M 
50.8 ± 13.1 
" M = male, F = female. 
" CS = chronic stationary psoriasis. 
, Relative chemotactic activity. 
8 
15 
26 
20 
13 
4 
20 
15.0 ± 6.6 
8 CS 50 7 
5 CS 30 24 
10 CS 50 5 
5 CS 50 25 
5 CS 50 3 
0.4 CS 50 15 
5 CS 50 37 
17.1 ± 1l.8 357.8 ± 113.7 
TABLE II. Clinical data in psoriatic patient:; with increased serum chemotactic activity 
Patient No. Age/sex Psoriasis since (yr) Relapse since Type of psori asis Extent of skin RCA " IgA (mg/dl) (yr) involvement (%) 
1 77 M 50 Weeks Erythroderma 100 318 102 
2 51 M 15 Weeks CS" 10 359 137 
3 17 F 9 Weeks Guttate 20 367 129 
4 50 M 10 1 CS 10 362 211 
5 47 M 20 1 CS 10 381 132 
6 22 M 1 1 Guttate 20 374 117 
7 18 F 3 0.5 Guttate 20 405 131 
8 38 M 8 0.5 Guttate 20 382 137 
9 31 M 8 Weeks Guttate 20 461 117 
10 53 F 39 1 CS 
40.4 ± 18.9 16.3 ± 16.0 
" RCA = relative chemotactic activ ity. 
" CS = chronic stationary psoriasis. 
In view of the fact that PMN chemotaxis and random migra-
tion is reported to be inhibited by IgA myeloma sera in contrast 
to IgG myeloma sera [11] the levels of IgA were quantitatively 
determined by using radial immunodiffusion. Average values 
for normal healthy persons were 164 ± 76 mg/ dl. In the control 
persons examined dming this study the average IgA serum 
levels were close to given standard data. In psoriasis IgA levels 
averaged 357.8 ± 113.7 mg/dl in the low responder grou p 
whereas sera with increased RCA showed low levels of IgA 
(134.9 ± 29.0 mg/dl) . The differences between the 2 IgA levels 
were significant (p < 0.001) . 
Comparison with Other Inflammatory Diseases 
In Table III various inflammatory skin diseases which were 
examined for serum chemotactic activity are reported. These 
include pyoderma gangrenosum, atopic dermatitis, chronic mu-
cocutaneous candidiasis, one patient with severe fi'stulating 
acne conglobata of the axilla and genito-crural region and a 
patient with Sweet syndrome. 
As can be seen inhibitory activity of serum chemotll.xis like 
that in psoriasis is present in a group of patients with pyoderma 
gangrenosum, the patient with acne conglobata and the patient 
with Sweet syndrome. The patients with atopic dermatitis 
showed slightly increased chemotactic activities. 
IgA levels paralleled the presence of serum inhibition of 
chemotaxis, the highest IgA value was found in the acne patient. 
Low IgA levels were seen in the atopic group (Table III) . 
For comparison RCA was determined in 10 patients with 
chronic arthl'itis following rheumatic fever and 10 patients with 
chronic glomerulonephritis (data not shown) . In addition, 30 
healthy persons served as controls. The results revealed abnor-
mallY low RCA in 5 patients with arthritis and one patient with 
nephri tis. IgA levels were not measured except for the controls 
(164 ± 76 mg/dl). 
10 379 136 
378.8 ± 36.5 134.9 ± 29.0 
TABLE III. Chemotactic activity and serum /gA levels in patients 
with various inflammatory shin diseases. 
Duration IgA Age/sex of disease RC A" 
()'l') (mg/ dJ) 
1. Pyoderma 67 M 11 6 592 
gangrenosum 70 F 1 22 769 , 
65 M 0.5 46 413 
40 M 0.2 152 201 
2. Acne conglobata 42 M 26 18 870 
3. Sweet syndrome 46 F 0.2 53 562 
4. Chron. M.C. 66 F 2.5 198 163 
Candidiasis 37 F 5 239 186 
5. Atopic 22 F s.b. " 284 105 
dermatitis 2 F s.b. 349 113 
18 F s.b. 350 87 
18 F s. b. 234 98 
47 M s.b. 322 159 
" RCA = R elative chemotactic activity. 
" s. b. means since birth. 
Effects of Serum Dilution upon PMN Chemotaxis 
Serum taken from a patient with long-standing wide-spread 
psoriasis was serially diluted with TC 199 after heat inactivation 
and assayed for RCA in the presence of PMA. Starting at a 
dilution of 1:32 of this patient's serum the inhibition of PMN 
migration is gradually lessened (Fig 3). As can be seen on the 
same graph the control serum exerts inhibitory effects when 
applied after 1:2 and 1:4 dilution (Fig 3)). PMN chemotactic 
migration is highest when heat inactivated control serum is 
diluted 1:8 to 1:64 in TC 199 and gradually falls off at further 
dilution steps. 
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RCA 
150 
100 
50 ! 
1,2 1'4 1.8 1'16 1'32 1·64 1'128 1·256 control 
FIG 3. Relative chemotactic activity (RCA, ordinate) of (-0-) non-
psoriatic control serum and (-x-) serum from a patient with c11l'onic 
stationary psoriasis after serial dilution with TC 199 in the presence of 
1 ng PMA per ml. The strong inhibit ion of RCA caused by psoriatic 
serum is gradually becoming smaller at serum dilutions of 1:32 and 1: 
64_ Control serum shows decreasing RCA values with increasing dilu-
tion possible due to diminution of albumin. 
RCA OD 280 Sephacryi S -3OO 
500 I,D 
,-"\ 
I \ 
I \ 
I I 
I \ 
I \ 
I \ 
I \j 
I 
I 
I I 
I I 
I I 
300 0,6 I I 
I I 
I I 
I I 
I I 
I I 
I I I 
I I 
200 0,.4 I 
I 
I I 
I I 
I 
, 
I 
, 
I 
, 
, 
I , 
100 0,2 I \ I \ 
,- -
I 
'I I 
I \ 
I \ 
,.// -, I , 
----" 
6 7 8 9 10 II 12 13 14 IS 16 17 20 22 24 29 
fraction number 
FIG 4. Column chl'Omatography (8ephacryl 8-300) of fresh serum of 
a patient with chronic stationary psoriasis correlated with relative 
chemotactic activity (RCA) of the elu tion fractions. PMA was used as 
potentiator of chemotaxis. Note strong inhibition of RCA with fraction 
numbers 9- 14. OD = optical density at 280 nm. 
Further Characterization of the Inhibitory Component(s) Pres-
ent in low Responder Sera 
Subsequently 10 sera of the low responder group were chro- . 
ll1atographed using Sephacryl S 300-column chromatography 
and the RCA of the eluent fractions were measw·ed. Inhibition 
of RCA was seen with fraction number 9 to 14 (Fig 4) while the 
rest revealed no major inhibitory activity. The main inhibitory 
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fractions eluted with an approximate molecular weight of 
200,000 Daltons. 
As revealed by the Mancini technique IgA was present in 
fraction number 9 to 13 only with a major peak in fraction 
number 11 (data not shown). These results indicate, that the 
inhibitory compound may be IgA. 
In addition to sera from patients with chronic stationary 
psoriasis (low responders of chemotaxis) serum from 4 healthy 
control persons the patient with acne conglobata as well as a 
patient with pyoderma gangrenosum were chroma to graphed in 
this manner. In all chromatograms except for the controls 
defined fractions with strong (80-100%) inhibition of chemotaxis 
were eluted. The inhibitory peaks were of the same molecular 
weight range (ca.200,OOO Daltons). 
DISCUSSION 
In studies reported recently a highly increased chemotactic 
activity was noted when PMNs from patients with psoriasis 
were confronted with autologous sera (fresh as well as heat 
inactivated) [5]. Since wide variations from patient to patient 
were seen attempts were made to more closely examine the 
chemotactic activity of serum under standardized conditions. 
These included the use of PMA, a known tumor promotor 
which recently has been shown to elicit membrane responses in 
human PMN [12]. White and Estensen demonstrated the se-
lective release of enzymes of the secondary (specific) granules, 
when the cells were incubated with PMA at a concentration of 
10 ng/ rnl [10]. By adding PMA at concentrations of l.0 ng and 
10 ng/rnl to E. coli bacterial fIltrate the chemotactic activity 
increased up to 700% [7]. This potentiation of leukotaxis by 
PMA is thought to derive from the stimulatory effect of PMA 
on cGMP levels already induced by the chemoattractant [13]. 
In the present study the addition of various concentrations 
of PMA to serum is followed by strong potentiation of RCA 
(Fig 1). This result confIrms the fIndings of Estensen et al [7) 
using a different chemoattractant. As shown below the poten-
tiation of RCA allows more precise discrimination between 
chemoattractant potencies of serum. 
Concentrating upon psoriatic sera we now observed that a 
proportion of patients (approximately 30% of the present pa-
tient grouping) shows abnormal chemotactic activities which 
range from nearly complete absence of migrating cells to greatly 
increased chemotactic activity. Analysis of the low responder 
sera as compared to high responders (Table I, II) leads to the 
notion, that patients with the persistent, stationary form of 
psoriasis are among the low responders. On the other hand 
patients with recent onset of psoriasis or recent relapses show 
high~.gerum chemotactic activity. In addition, the extent of skin 
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FIG 5. Correlation of serum IgA and the chemotactic activity of 
serum in patients with psoriasis. T here is nearly complete absence of 
RCA at high IgA levels. 
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involvement in both groups differs greatly with the low re-
sponder group showing considerably more skin affected (50% 
surface covered) as compared to the high responder group. 
Interestingly the inhibitory effect on the migration of normal 
PMNs was also present in PG, severe acne conglobata and 
several patients with arthritis. Patients with atopic dermatitis 
or glomerulonephritis were included in this study as represent-
atives of chronic inflammatory diseases without the predomi-
nant involvement of neutrophils. Since no inhibition of RCA 
was found in the latter diseases, our results indicate, that the 
inhibition of RCA may be related to tissue alterations in which 
PMN playa major role. 
Furthermore our data suggest a close correlation between the 
levels of circulating IgA and chemotactic inhibition in psoriasis 
as well as in other neutrophil related dermatoses (Fig 5). As an 
example in patients with chronic stationary psoriasis IgA values 
were increased ranging from 224 to 575 mg/dl (Table II). This 
is in accordance with the findings of Marghescu and Braun-
Falco [14] and more recently Guilhou et al [15] who found 
elevated IgA levels in generalized psoriasis. As shown (Table I) 
these patients demonstrate strong inhibition of RCA. In con-
trast patients with increased RCA (Table II) showed average 
IgA levels of 134.9 mg/dl. 
This correlation between the ability of heat inactivated serum 
to inhibit the migratory response of normal PMNs and the 
serum level of IgA, also seen in PG as well as in the patient 
with acne conglobata and the case of Sweet syndrome (Table 
III) may be a secondary phenomenon due to a prolonged 
neutrophil related inflammatory response. Recent studies have 
shown that isolated IgA paraproteins inhibit neutrophil che-
motaxis [11], bactericidal activity [16] and normal serum IgA 
inhibits phagocytosis of C. albicans [17]. The polymeric (aggre-
gated) forms of IgA appear to be responsible for most of these 
effects on PMN function [11). Kemp, Cripps, and Brown ob-
served that isolated IgA from normal human serum inhibits 
both random as well as chemotactic migration of human PMN 
[18). It, is felt that the inhibitory activity may be due to the 
aggregated forms of IgA as produced during the isolation pro-
cedure. Native monomeric IgA present in normal serum is 
found not to inhibit PMN migl"ation [18]. It has been postulated 
that polymeric IgA binds to IgA receptors on the PMN [11,19] 
and that chemotaxis is suppressed by the Fc receptor binding 
of IgA [16). . 
The present results indicate IgA-associated inhibition of che-
motaxis. This inhibition is shown to be increased in diseases, in 
which PMNs playa major role. The inhibiting principle con-
sistently showed a molecular weight of approximately 200,000 
Daltons, which is close to the mol. weight of IgA. By radial 
immunodiffusion it was demonstrate that this immunoglobulin 
was present only in the inhibitory fractions. Therefore it ap-
Vol. 77, No.6 
pears that the serum factor responsible for the inhibition of 
human neutrophil chemotaxis is IgA. Further confirmation will 
be obtained by affinity chromatography, which is in progress. 
We are greatful to Miss C. Mehrens for technical assistance and to 
Mrs. I. Kablitz for typing the manuscript. 
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